Elemer Piros

Elemer Piros Recent News

Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway
Cantor Fitzgerald Bullish On GW Pharmaceuticals, Sees 75% Upside Potential
Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'
GW Pharma's Epidiolex Becomes First CBD To Get DEA Rescheduling
Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals
Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment
Glaukos Has 84% Upside Potential In 2018, According To Cantor
Analyst: Weakness In Spark Therapeutics Is Overdone
After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target
Can Omeros Top-Line Growth Continue?
At Long Last, Dynavax Wins FDA Approval For Heplisav
Bluebird Bio Price Target Bumped To $58 On Directional Improvements
Analyst Sees 243% Upside For Corbus Pharma Following Positive Clinical Data
Spark Therapeutics: Inside The Dramatic FDA AdCom Meeting
Aerie Pharma's FDA Briefing Docs: Good News With No Surprises; Shares Scale a Record
Analyst Upgrades Zynerba, Encouraged By Prospects For Fragile X Phase 2 Study
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
Versartis' Somavaratan Still Has A Path Forward; Cantor Reiterates Buy
Is GW Pharma Now The Future Of Cannabis-Based Drugs?
Zynerba's Clinical-Trial Miss Devastates Stock Price
Canton Fitzgerald Reiterates Overweight Rating, $28 Price Target On Zynerba
Intercept Pharma Analysts See Growth Ahead, But Keep Underweight Rating For Now
Cantor Remains Confident On Ocular Therapeutix Despite Big Decline